Answers are grounded in this paper and cite their sources.
Rheumatoid arthritis (RA) synovial lesions are sustained by interacting redox, immune, metabolic, and osteoimmune abnormalities. Nanozymes offer a means of modifying these microenvironmental processes, but the therapeutic activity of a complete formulation should not be equated with an independently established catalytic contribution. This critical narrative review organizes RA-related nanozyme research by pathological axis, treatment mode, and evidence maturity. An author-defined three-tier framework distinguishes animal therapeutic evidence with validated catalytic attribution from formulation-level efficacy and mechanistic or cross-disease observations. None of the representative studies appraised here establishes the complete Type A evidence chain under the stated criteria. Antioxidant and immunomodulatory activity, together with structural protection in selected experiments, supports further investigation of these platforms; however, drug delivery, targeting, material degradation, and externally applied energy frequently complicate causal interpretation. NET-directed interventions illustrate an additional distinction between suppressing trap formation, modifying neutrophil fate, and degrading pre-existing traps. Translational limitations include uncertain catalytic performance in synovial fluid, incomplete exposure and clearance measurements, limited repeated-dose safety evaluation, and heterogeneous comparisons with established antirheumatic therapies. Future studies should prioritize disease-relevant catalytic assays, validated attribution controls, treatment of established arthritis, structural and functional outcomes, and formulation-specific safety. These requirements define a research agenda rather than evidence of clinical readiness.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: